Skip to main content
Clinical Trials/NCT02600156
NCT02600156
Completed
Not Applicable

A Pilot Study to Evaluate Magnetic Resonance Thermal Image-Guided Focal Laser Ablation of Prostate Cancer Tumors

Mayo Clinic1 site in 1 country7 target enrollmentSeptember 1, 2015

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prostate Cancer
Sponsor
Mayo Clinic
Enrollment
7
Locations
1
Primary Endpoint
Incidence of treatment emergent adverse events
Status
Completed
Last Updated
4 months ago

Overview

Brief Summary

The primary purpose of this study is to evaluate the feasibility and safety of MRI-guided focal laser ablation (Laser-Induced Interstitial Thermal Therapy, LITT) to treat low-risk native prostate cancer.

Detailed Description

The study is being done to evaluate the safety and effectiveness of Magnetic Resonance Imaging (MRI)-guided focal laser therapy with the Visualase Thermal Therapy System to treat low-risk prostate cancer tumors. Unlike surgery or radiotherapy which affects a large portion of the prostate or the entire organ, localized or focal therapy is intended to treat a small portion of tissue in which the cancer has been found by biopsy.

Registry
clinicaltrials.gov
Start Date
September 1, 2015
End Date
December 9, 2025
Last Updated
4 months ago
Study Type
Interventional
Study Design
Single Group
Sex
Male

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David A. Woodrum

David A. Woodrum, M.D., Ph.D.

Mayo Clinic

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Incidence of treatment emergent adverse events

Time Frame: 3 years

To evaluate patient-related safety by monitoring short and long-term complications related to the procedure such as but not limited to incontinence, impotence, and urethral fistulas.

Success rate

Time Frame: 3 years

To evaluate the procedural success rate of using the MR-guided laser ablation to target, access, thermally monitor, and focally ablate MR-visible prostate cancer lesions.

Secondary Outcomes

  • Short- and mid-term ablative success(3 years)

Study Sites (1)

Loading locations...

Similar Trials